e-learning
resources
Barcelona 2013
Monday, 09.09.2013
Modern approach to various clinical settings
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Clinical and functional effectiveness of roflumilast in severe COPD patients
Y. Feshchenko, L. Iashyna, M. Polianska, S. Moskalenko (Kiev, Ukraine)
Source:
Annual Congress 2013 –Modern approach to various clinical settings
Session:
Modern approach to various clinical settings
Session type:
Thematic Poster Session
Number:
2196
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Y. Feshchenko, L. Iashyna, M. Polianska, S. Moskalenko (Kiev, Ukraine). Clinical and functional effectiveness of roflumilast in severe COPD patients. Eur Respir J 2013; 42: Suppl. 57, 2196
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Static lung volumes and spirometry measurements
Panel discussion: The role of pharmacotherapy connected to OSA pathophysiological traits
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
Roflumilast added to triple therapy in severe COPD patients with frequent exacerbations: Efficacy and tolerability
Source: International Congress 2014 – Markers
Year: 2014
Can roflumilast improve clinical outcomes in moderate-to-severe chronic obstructive pulmonary disease? A meta-analysis
Source: International Congress 2016 – COPD diagnosis and management
Year: 2016
Efficacy of roflumilast with concomitant cardiovascular medication in patients with COPD
Source: Annual Congress 2013 –Novel mechanisms for established drugs for asthma and COPD management
Year: 2013
The role of IFN-γ in severe COPD patients with anamnestic viral-induced exacerbations before and after roflumilast treatment
Source: International Congress 2016 – Translational studies in lung disease
Year: 2016
Clinical, functional and laboratory assessment of treatment efficacy in COPD patients
Source: International Congress 2014 – Predictors
Year: 2014
COPD on anti-GERD therapy remains at higher risk for severe exacerbation
Source: International Congress 2014 – COPD exacerbations
Year: 2014
The clinical impact of long-acting bronchodilators in newly diagnosed COPD patients
Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics
Year: 2013
Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trial
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015
Clinical characteristics of patients with frequent COPD exacerbations in a Swiss multicenter COPD cohort study (TOPDOCS)
Source: International Congress 2016 – Targeting care, pulmonary rehabilitation, management, and self-management of COPD exacerbations in primary care
Year: 2016
Assessment of efficacy and tolerability of roflumilast add-on to LABA/LAMA/ICS in the treatment of COPD in Indian patients
Source: International Congress 2016 – Novel avenues in the treatment of COPD I
Year: 2016
QVA149 improves lung function and reduces exacerbations compared to tiotropium in patients with severe-to-very severe COPD: The SPARK study
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013
Sit-to-stand ability in patients hospitalised for acute exacerbation of COPD: Clinical characteristics and short-term outcomes
Source: International Congress 2015 – New insights into exercise and muscle performance
Year: 2015
Onbrace: A real-life evaluation of indacaterol maintenance treatment for COPD
Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Year: 2016
Clinical management of very severe COPD
Source: Annual Congress 2008 - Update on long-term oxygen therapy in COPD
Year: 2008
Compare clinical effectiveness of various types of bronchodilators in COPD patients
Source: International Congress 2016 – Novel avenues in the treatment of COPD I
Year: 2016
Impact of frequent exacerbations in patients with COPD
Source: International Congress 2014 – Clinical presentations
Year: 2014
QVA149 reduces the risk of moderate-to-severe exacerbations compared with open-label tiotropium in patients with severe COPD: The SPARK study
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Integrated care reduces hospital utilization among patients with severe COPD
Source: International Congress 2014 – COPD exacerbations
Year: 2014
QVA149 reduces COPD exacerbation rate in various subgroups of patients: The SPARK study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013
Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trials
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept